ArticleThe Pediatric infectious disease journal2012
Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Article in The Pediatric infectious disease journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2020Pooled it
- A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.The Pediatric infectious disease journal · 2018Trial
- Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using anAntimicrobial agents and chemotherapy · 2021Article
- Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.The Pediatric infectious disease journal · 2018Article
- Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Clinical pharmacokinetics · 2018Review
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection · 2017Review
- Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.Clinical pharmacokinetics · 2017Article
- Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.Paediatric drugs · 2017Review
- Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.Antimicrobial agents and chemotherapy · 2015Article
- Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.European journal of drug metabolism and pharmacokinetics · 2015Article
- Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.Antimicrobial agents and chemotherapy · 2015Observational
- Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clinical pharmacokinetics · 2014Review
- Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.The Pediatric infectious disease journal · 2013Article
- Development and validation of a stability-indicating high performance liquid chromatographic (HPLC) method for the determination of related substances of micafungin sodium in drug substances.International journal of molecular sciences · 2013Article
- Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Drugs · 2012Review
- Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.The Pediatric infectious disease journal · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although micafungin pharmacokinetic values were comparable between younger (<5 years) and older children (≥5 years) with candidemia and invasive candidiasis, younger children had a lower peak plasma micafungin concentration, lower micafungin exposure and larger micafungin clearance. Half-life remained unchanged with repeated dosing. Metabolite plasma concentrations remained low in older children; however, metabolite M-5 concentrations were higher in younger children.
Indexed as
Identifiers
22301478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.